Pralsetinib, chemically known as (((R)-3-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)-1-((1s,4S)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl) cyclohexyl) butan-1-one--(S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl) ethan-1-amine), a highly selective RET inhibitor (Griesinger et al., 2022), was approved by the China National Medical Products Administration in March 2021 for the treatment of locally advanced or metastatic non-small cell lung cancer in adult patients with RET gene fusion who previously received platinum-based chemotherapy. Here, RET is linked to non-small cell lung carcinoma.